Video

Intermittent, but prolonged, calorie restriction may improve metabolic markers


 

REPORTING FROM ENDO 2019

– Can a physician-supervised, intermittent fasting strategy improve metabolic risk? Yes, according to Valter Longo, PhD.

Dr. Longo is a proponent of 5 days of reduced calories, performed once monthly or even less frequently for at-risk individuals. He calls this the “fasting-mimicking diet.”

“If somebody is obese or overweight, and has high cholesterol, high fasting glucose, and is perhaps prediabetic, then a doctor may decide to do the diet once a month for 5 days, and for the rest of the month, the person can go back to whatever it is that they do,” he said in a video interview at the annual meeting of the Endocrine Society.

“We think we are going to see more and more of this approach in the future,” said Dr. Longo, the Edna M. Jones Professor of Gerontology at the University of Southern California, Los Angeles.

Dr. Longo sees two chief practical benefits from the diet. First, patients “don’t feel they are being pushed to revolutionize their lives” because they aren’t asked to make radical lifestyle changes that have to be adhered to on a daily basis, and second, “we are starting to see that the patient slowly moves in the direction of a better diet without being asked to do it.”

A clinical trial with about 100 patients showed improvements in many metabolic markers after 3 months of a once-monthly, 5-day cycle of the low-calorie diet, which includes some healthy fats from olive oil and nuts. Fasting blood glucose, blood pressure, and insulinlike growth factor 1 levels and other metabolic markers were all reduced in the randomized crossover trial after 3 months of the diet plan.

Dr. Longo noted that in the clinical trial, effects were more pronounced for individuals with a higher risk for disease.

Dr. Longo has a majority stake in L-Nutra, which markets a commercially available fasting-mimicking diet package. He donates his proceeds to a nonprofit corporation he founded.

Recommended Reading

Real-world weight loss with meds approximates RCT results
MDedge Cardiology
Opioids don’t top NSAIDs for chronic pain
MDedge Cardiology
‘Payoff will be great’ if we can conquer childhood obesity, expert says
MDedge Cardiology
Firibastat looking good for difficult-to-treat hypertension
MDedge Cardiology
Cerebral small vessel and cognitive impairment
MDedge Cardiology
Prenatal valproate and ADHD
MDedge Cardiology
Gender, racial, socioeconomic differences found in obesity-depression link
MDedge Cardiology
Obesity paradox applies to post-stroke mortality
MDedge Cardiology
FDA accepts supplemental New Drug Application to expand lorcaserin label
MDedge Cardiology
Oxytocin dampens the brain’s food-related reward circuitry
MDedge Cardiology